American College of Rheumatology (ACR) response to treatment at weeks 2 and 12. Results are shown as number (%)
| Degree of improvement | Placebo (n = 70)* | Adalimumab | |||
|---|---|---|---|---|---|
| 20 mg (n = 71)* | 40 mg (n = 70)* | 80 mg (n = 72)* | All doses (n = 213)* | ||
| *Group numbers indicate initial size of each group, with the exception of the adalimumab 20 mg group, which does not include the patient with Felty’s syndrome who was withdrawn after the first dose. Withdrawals and rescues were considered treatment failures. | |||||
| Comparison v placebo (Pearson’s two sided χ2 test, α = 0.05): †p⩽0.001; ‡p⩽0.01; §p⩽0.05. | |||||
| ⩾20% (ACR20) | |||||
| Week 2 | 2 (3) | 22 (31)† | 27 (39)† | 33 (46)† | 82 (38)† |
| Week 12 | 7 (10) | 36 (51)† | 40 (57)† | 39 (54)† | 115 (54)† |
| ⩾50% (ACR50) | |||||
| Week 2 | 0 (0) | 2 (3) | 4 (6) | 5 (7) | 11 (5) |
| Week 12 | 1 (1) | 17 (24)† | 19 (27)† | 14 (19)† | 50 (23)† |
| ⩾70% (ACR70) | |||||
| Week 2 | 0 (0) | 0 (0) | 1 (1) | 1 (1) | 2 (1) |
| Week 12 | 0 (0) | 8 (11)‡ | 7 (10)‡ | 6 (8)§ | 21 (10)‡ |